Skip to contentpdufa.bio

IDVYNSO (doravirine and islatravir): FDA NDA 216964

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 216964 is the FDA application for IDVYNSO (doravirine and islatravir). The FDA's Orange Book lists the applicant of record as MERCK SHARP AND DOHME LLC and the first approval on it as Apr 20, 2026. Code name used in development: MK-8591A. Owner today: Merck & Co., Inc. (NYSE: MRK).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 216964 · Orange Book NDA 216964

Names for this drug

Brand name (FDA)IDVYNSO
Orange Book trade name: IDVYNSO
Active ingredient (FDA)DORAVIRINE; ISLATRAVIR
Code nameMK-8591A
Source: Merck press release, Feb 25, 2026
“doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK-8591A)] in adults with HIV-1”

Who holds the application

FDA applicant of recordMERCK SHARP AND DOHME LLC
FDA Orange Book data files as of Nov 13, 2026
Owner todayMerck & Co., Inc. (MRK)
Source: Merck press release, Apr 21, 2026
“Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today”

Products on NDA 216964 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001IDVYNSOTABLET;ORAL100MG;0.25MGApr 20, 2026

FDA decisions we track for this drug

IDVYNSO - treatment-naive HIV-1 (P053) and 96-week data (sNDAs)MRK · Upcoming

Drug page: /drug/idvynso

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.